This study has immediate implications for patient management.

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor mutation in tumors as Caucasians, which suggests they are as more likely to benefit from targeted therapies such as for example erlotinib . This study has immediate implications for patient management. Individuals with EGFR mutations possess a far greater prognosis and respond better to erlotinib than those who do not, stated Ramsi Haddad, Ph.D., director of the Laboratory of Translational Oncogenomics at the Barbara Ann Karmanos Cancer tumor Institute, and associate professor at Wayne State University School of Medicine.

In other cases, researchers may use eligibility criteria to enroll only desirable patients within their study, in order to make the trial run smoothly or to raise the chances that a favored treatment will show positive outcomes. Humphreys stated such exclusions could have dangerous implications. If treatments are tested on, and created for, only portion of the population, which means everyone excluded is at greater risk if they use health care, stated Humphreys. For this good reason, the National Institutes of Health has instructed experts to create their studies to make sure adequate enrollment of all populations, including women and racial minorities.